Clinicians sought potential therapeutic options for individuals with poor prognoses in two others; one with T-ALL and CD4/CD8 double negative immunophenotypeand one with infantile B-ALL (2/18, 11.1%). The gene discussed is CD8A; the disease is acute lymphoblastic leukemia.